Imipramine
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Imipramine: From Anxiety Disorder to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Imipramine is a tricyclic antidepressant, originally used for anxiety disorder, neurotic disorder, dysthymic disorder and nocturnal enuresis. The TxGNN model predicts it may be effective for attention deficit-hyperactivity disorder (ADHD), with no registered clinical trials but 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorder, neurotic disorder, dysthymic disorder, nocturnal enuresis (from the knowledge graph; the Singapore licence records contain no approved indication text) |
| Predicted New Indication | Attention deficit-hyperactivity disorder |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for imipramine is not available in the data compiled for this report. Based on its known pharmacology, imipramine blocks the reuptake of norepinephrine and, to a lesser extent, serotonin. Boosting noradrenaline signalling in prefrontal circuits is also the principle behind atomoxetine and other non-stimulant ADHD treatments.
Imipramine's established uses (anxiety, neurotic and dysthymic disorders, bedwetting) are all neuropsychiatric conditions that respond to monoamine modulation. ADHD, often accompanied by anxiety and enuresis, shares this neurochemical basis. Reviews in the literature describe imipramine and desipramine as non-stimulant options, mainly when stimulants fail.
Stimulants and non-stimulants such as atomoxetine remain the preferred first-line options. Imipramine would be a later-line alternative.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Of 20 publications retrieved, the most relevant are listed below. Study-design labels for several older papers could not be verified.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34002501 | 2021 | Network meta-analysis | World Psychiatry | Umbrella review of the efficacy and acceptability of drug, psychosocial and brain-stimulation interventions in children and adolescents with mental disorders, including ADHD |
| 32982805 | 2020 | Meta-review | Front Psychiatry | Efficacy, tolerability and suicidality of antidepressants in young people, including for ADHD and enuresis |
| 10790990 | 1999 | Review | Evid Rep Technol Assess | Evidence report on drug and non-drug ADHD treatments in children and adults |
| 31776871 | 2019 | Review | CNS Drugs | Pharmacokinetic drug interactions of ADHD agents |
| 15794722 | 2005 | Review | Expert Opin Drug Saf | Safety of non-stimulant ADHD agents; imipramine and desipramine may be effective, atomoxetine is second-line |
| 17078784 | 2006 | Clinical study | Expert Rev Neurother | Norepinephrine reuptake inhibitors (desipramine, imipramine, atomoxetine) can be effective; P300 topography used to guide treatment choice |
| 6849467 | 1983 | Clinical study (design to be verified) | Am J Psychiatry | Dedicated report on imipramine for attention deficit disorder |
| 18304665 | 2008 | Clinical study | Int J Psychophysiol | Effects of imipramine on the EEG of children with ADHD who did not respond to stimulants |
| 9465283 | 1996 | Clinical study | Clin EEG | Prolonged P300 latency predicted poor imipramine response in 17 children who had responded poorly to pemoline |
| 14501767 | 2003 | Clinical study | J Urol | Management of urinary incontinence and nocturnal enuresis in children with ADHD |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN04154P | AA PHARMA IMIPRAMINE TABLET 25MG | Film-coated tablet | Not listed in the registration record |
| SIN04155P | AA PHARMA IMIPRAMINE TABLET 10MG | Film-coated tablet | Not listed in the registration record |
Both are single-ingredient oral products from Apotex Inc and are currently valid.
Safety Considerations
- Contraindications (knowledge-graph associations, not package-insert text): epilepsy; bipolar disorder and major affective disorder; kidney, liver and gallbladder disease; blood disorders (thrombocytopenia, neutropenia, agranulocytosis); benign prostatic hyperplasia; substance abuse/dependence; cardiovascular conditions (coronary artery disease, heart disease, heart conduction disease, sudden cardiac arrest); stroke and other cerebrovascular disorders; ileus and intestinal obstruction; ocular hypertension and angle-closure glaucoma; hyperthyroidism (Graves disease, thyrotoxicosis).
- Drug Interactions: 100 interactions were recorded, and a medication review is required. Examples of Major interactions include epinephrine, bupropion, lorcaserin, potassium citrate and dolasetron. Moderate examples include famotidine, cimetidine, clarithromycin, morphine, acetylsalicylic acid, and anticholinergics (atropine, hyoscyamine, glycopyrronium, dicyclomine).
- Points of attention for this indication: cardiac toxicity (QTc and conduction effects), anticholinergic burden, lethality in overdose, and safety in children.
The package-insert warnings and contraindications have not been compiled. Please refer to the package insert for the full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Imipramine has a plausible noradrenergic mechanism and a dedicated body of literature in ADHD, including reviews and a 2021 network meta-analysis. No registered trials exist, and the design of the primary studies is unverified, so evidence is capped at L3. Established first-line alternatives (stimulants, atomoxetine) also make it a later-line option.
To proceed, the following is needed:
- Package-insert warnings and contraindications from the HSA (a blocking gap for safety screening)
- Detailed mechanism-of-action data
- Verification of the designs of the primary imipramine ADHD studies (e.g. PMID 6849467, 18304665)
- A cardiac monitoring plan (ECG) and a paediatric dosing and overdose-safety plan
- A medication-review process for the 100 recorded drug interactions
Other Predicted Indications (Brief)
| Predicted Indication | TxGNN Score | Evidence Level | Decision | Note | |------|------|------|------|------| | Agoraphobia | 98.97% | L2 | Proceed with Guardrails | Strongest evidence of the alternatives: multiple controlled studies of imipramine in panic disorder with agoraphobia (e.g. 6101535, 3512534, 7726306) and a 2023 Cochrane network meta-analysis (38014714). SSRIs are now first-line, so imipramine is second-line. | | Obsessive-compulsive disorder | 99.01% | L3 | Research Question | Small comparative studies suggest weaker efficacy than clomipramine and SSRIs. | | ADHD, inattentive type | 99.83% | L5 | Hold | Model prediction only; no subtype-specific evidence. | | Specific developmental disorder | 99.67% | L4 | Hold | Only indirect, off-target literature. | | Faciodigitogenital syndrome, chondromyxoid fibroma, benign paroxysmal torticollis of infancy, histrionic personality disorder, schizoid personality disorder | 98.61%–99.80% | L5 | Hold | No trials or literature and no clear mechanistic link. |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.